Table 1 Characteristics of the study patients
From: Glycated hemoglobin and glycated albumin in patients with diabetes undergoing hemodiafiltration
Variable | |
|---|---|
Number of patients (M/F) | 133 (81/52) |
Age (years) | 68.7 ± 13.3 |
Dialysis history (months) | 78.3 ± 67.1 |
Dialysis time (h) | 3.7 ± 1.0 |
Blood flow rate (mL/min) | 204.7 ± 29.6 |
Dialysate flow rate (mL/min) | 531.8 ± 46.8 |
Replacement fluid volume (L) | 45.0 ± 14.8 |
Dry weight (kg) | 56.2 ± 14.1 |
Albumin (g/dL) | 3.4 ± 0.4 |
UN (mg/dL) | 60.6 ± 14.8 |
Hb (g/dL) | 10.6 ± 1.0 |
Ht (%) | 32.5 ± 3.2 |
Pre-dialysis blood glucose (mg/dL) | 138.4 ± 45.4 |
HbA1c (%) | 6.0 ± 0.9 |
GA (%) | 20.4 ± 4.7 |
Fe (μg/dL) | 59.7 ± 23.1 |
TIBC (μg/dL) | 206.3 ± 46.1 |
TSAT (%) | 30.0 ± 12.4 |
Ferritin (ng/dL) | 261.0 ± 187.6 |
ESAs | |
Darbepoetin alfa (μg /week) (number) | 21.1 ± 17.4(98) |
epoetin beta (U/week) (number) | 3187.5 ± 1060.7(2) |
epoetin beta pegol (μg /week) (number) | 22.7 ± 9.8(11) |
ERI (each ESA dose/kg/g/dL/week) | |
Darbepoetin alfa (number) | 0.04 ± 0.04(98) |
Epoetin beta (number) | 5.2 ± 1.5(2) |
Epoetin beta pegol (number) | 0.04 ± 0.02(11) |
Iron (intravenous administration) | |
Saccharated ferric oxide (mg/week) (number) | 44.2 ± 29.0(45) |
Iron-based phosphate binder (oral administration) | |
Sucroferric oxyhydroxide (mg/week) (number) | 8361.1 ± 5233.8(9) |
Ferric citrate hydrate (mg/week) (number) | 11940.3 ± 6267.9(22) |